| Literature DB >> 24185843 |
Rosa Ortiz-Gutiérrez1, Roberto Cano-de-la-Cuerda, Fernando Galán-del-Río, Isabel María Alguacil-Diego, Domingo Palacios-Ceña, Juan Carlos Miangolarra-Page.
Abstract
Postural control disorders are among the most frequent motor disorder symptoms associated with multiple sclerosis. This study aims to demonstrate the potential improvements in postural control among patients with multiple sclerosis who complete a telerehabilitation program that represents a feasible alternative to physical therapy for situations in which conventional treatment is not available. Fifty patients were recruited. Control group (n = 25) received physiotherapy treatment twice a week (40 min per session). Experimental group (n = 25) received monitored telerehabilitation treatment via videoconference using the Xbox 360® and Kinect console. Experimental group attended 40 sessions, four sessions per week (20 min per session).The treatment schedule lasted 10 weeks for both groups. A computerized dynamic posturography (Sensory Organization Test) was used to evaluate all patients at baseline and at the end of the treatment protocol. Results showed an improvement over general balance in both groups. Visual preference and the contribution of vestibular information yielded significant differences in the experimental group. Our results demonstrated that a telerehabilitation program based on a virtual reality system allows one to optimize the sensory information processing and integration systems necessary to maintain the balance and postural control of people with multiple sclerosis. We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.Entities:
Mesh:
Year: 2013 PMID: 24185843 PMCID: PMC3863866 DOI: 10.3390/ijerph10115697
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Inclusion and exclusion criteria.
| Inclusion criteria | Exclusion criteria |
|---|---|
|
Age between 20 and 60 years Confirmed diagnosis of MS for over 2 years based on McDonald criteria [ Medically stable during the 6 months prior to baseline Impaired balance associated with demyelinated lesions in the cerebellum and its connections EDSS score ranging from 3 to 5; Hauser ambulatory index value higher than 4 Absence of cognitive impairment according to the mini mental state examination test No visual deficits Internet connection at home. The level of experience with consoles and video games was not a criterion for the recruitment of patients. |
Diagnosed with another disease or pathological condition that affects balance Had an attack in the month prior to baseline or during the intervention process Received an intravenous or oral steroid cycle prior to beginning the evaluation protocol and within the 4-month duration of the project intervention |
MS: Multiple Sclerosis; EDSS: Expanded Disability Status Scale.
Sociodemographic characteristics.
| Variable | Group | Mean | SD | |
|---|---|---|---|---|
| Age (years) | Experimental Control | 39.69 | 8.13 | |
| 42.78 | 7.38 | 0.061 | ||
| Sex | Experimental Control | Women 54.2 % ( | ||
| Men 45.8% ( | ||||
| Women 60.9% ( | ||||
| Men 9.1 % ( | ||||
| Years since diagnosis | Experimental Control | 9.68 | 6.76 | |
| 10.86 | 5.40 | 0.142 | ||
| MS type | Experimental Control | PP 20.0 % ( | ||
| RR 71.9 % ( | ||||
| SP 8.1 % ( | ||||
| PP 8.7% ( | ||||
| RR 65.2% ( | ||||
| SP 26.1% ( | ||||
| EDSS | Experimental Control | Score 3 EDSS 16.4 % ( | ||
| Score 4 EDSS 75.5 % ( | ||||
| Score 5 EDSS 8.1 % ( | ||||
| Score 3 EDSS 21.7 % ( | ||||
| Score 4 EDSS 60.9 % ( | ||||
| Score 5 EDSS 17.4 % ( |
MS: Multiple Sclerosis; PP: Primary Progressive; RR: Relapsing Remitting; SP: Secondary Progressive.
t-test results of the within-group differences from pre- to post-treatment.
| Variable | Group | PRE-TREATMENT | POST-TREATMENT | F | Sig. | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± DE | 95% IC | Mean ± DE | 95% IC | ||||||
| Min. | Max. | Min. | Max. | ||||||
| Control | 62.85 ± 12.17 | 58.48 | 67.23 | 64.78 ± 9.70 | 61.34 | 69.22 | 37.873 | ||
| Experimental | 62.37 ± 11.35 | 58.02 | 66.72 | 70.58 ± 9.68 | 66.07 | 75.09 | |||
| Control | 85.58 ± 8.68 | 79.81 | 91.36 | 85.92 ± 7.36 | 81.39 | 90.45 | 2.909 | 0.095 | |
| Experimental | 85.27 ± 17.26 | 79.62 | 90.92 | 87.57 ± 8.44 | 82.89 | 92.24 | |||
| Control | 121.55 ± 23.93 | 110.55 | 132.55 | 120.55 ± 25.37 | 111.18 | 129.93 | 15.051 | ||
| Experimental | 117.82 ± 23.68 | 108.03 | 127.61 | 133.11 ± 20.79 | 122.96 | 143.27 | |||
| Control | 45.44 ± 12.45 | 42.48 | 48.41 | 45.02 ± 17.79 | 41.43 | 48.61 | 12.156 | ||
| Experimental | 40.54 ± 19.93 | 33.68 | 47.41 | 53.28 ± 15.85 | 46.36 | 60.20 | |||
| Control | 89.29 ± 11.08 | 85.04 | 93.54 | 93.76 ± 7.20 | 89.99 | 97.50 | 0.117 | 0.734 | |
| Experimental | 90.70 ± 9.12 | 86.20 | 93.98 | 92.47 ± 8.67 | 89.42 | 95.53 | |||
Significant (p < 0.05); CES: Composite Equilibrium Score; PREF: Visual Preference Ratio; VEST: Vestibular Ratio; ViR: Visual Ratio; SR: Somatosensory Ratio.
Descriptive statistics and marginal measures for pre- and post-treatment ANOVA between groups.
| Variable | Group | PRE-TREATMENT | POST-TREATMENT | F | |||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | 95% CIs | Mean ± SD | 95% CIs | ||||||
| Min. | Max. | Min. | Max. | ||||||
| CG | 62.85 ± 12.17 | 58.48 | 67.22 | 64.78 ± 9.70 | 61.33 | 69.22 | 37.873 | ||
| EG | 62.37 ± 11.35 | 58.02 | 66.72 | 70.58 ± 9.68 | 66.07 | 75.09 | |||
| CG | 85.58 ± 8.68 | 79.81 | 91.36 | 85.92 ± 7.36 | 81.39 | 90.46 | 2.909 | 0.095 | |
| EG | 85.27 ± 17.26 | 79.61 | 90.92 | 87.57 ± 8.44 | 82.89 | 92.24 | |||
| CG | 121.55 ± 23.93 | 110.55 | 132.55 | 120.55 ± 25.37 | 111.18 | 129.93 | 15.051 | ||
| EG | 117.82 ± 23.68 | 108.03 | 127.60 | 133.13 ± 20.79 | 122.96 | 143.27 | |||
| CG | 45.44 ± 12.45 | 42.47 | 48.41 | 45.02 ± 17.79 | 41.43 | 48.616 | 12.156 | ||
| EG | 40.54 ± 19.93 | 33.68 | 47.41 | 53.28 ± 15.85 | 46.37 | 60.203 | |||
| CG | 89.29 ± 11.08 | 85.03 | 93.54 | 93.76 ± 7.20 | 89.99 | 97.501 | 0.117 | 0.734 | |
| EG | 90.37 ± 9.12 | 86.20 | 93.98 | 92.48 ± 8.67 | 89.42 | 95.534 | |||
* Significant (p < 0.05; expressed as mean difference; 95% CIs. min-max); CES: Composite Equilibrium Score; PREF: Visual Preference Ratio; VEST: Vestibular Ratio; ViR: Visual Ratio; SR: Somatosensory Ratio.